Clinical Pathways for Acute Coronary Syndromes in China - phase 2: implementation and evaluatio

Not Applicable

Recruiting

• Conditions: Acute Coronary Syndromes; Cardiovascular - Coronary heart disease

• Registration Number: ACTRN12609000491268
• Lead Sponsor: Sanofi-Aventis (China)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-06-19
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 15000

Inclusion Criteria

Hospitals routinely admitting patients with acute coronary syndromes are included in the study; patients over 17 years old and being hospitalised due to acute coronary syndromes are included in the study.

Exclusion Criteria

Hospitals currently admitting fewer than 100 patients with suspected acute coronary syndromes per year will be excluded from the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Proportion of ST elevated myocardial infarction patients arriving at hospital within 12 hours of symptom onset who receive thrombolysis or primary percutaneous coronary intervention[Before and after the intervention];Proportion of patients with final diagnosis (unstable angina pectoris or myocardial infarction) consistent with biomarker findings (blood test results for Creatine Phosphokinase and Triponin)[Before and after the intervention];Door-to-needle time for ST elevated myocardial infarction patients undergoing thrombolysis[Before and after the intervention]

Secondary Outcome Measures

Name	Time	Method
Proportion of high-risk patients undergoing coronary angiography[Before and after the intervention];Proportion of low-risk patients (no ongoing symptoms, persistently normal Electrocardiography, persistently normal serum Creatine Phosphokinase and Triponin value) undergoing functional testing (exercise test and stress echocardiography)[Before and after the intervention];Proportion of patients discharged on appropriate medical therapy for secondary prevention (antiplatelets, beta-blockers, Angiotensin-Converting Enzymeinhibitors (ACE) inhibitors and statins being prescripted when patients are discharged )[Before and after the intervention];Mean length-of-stay in hospital[Before and after the intervention];Door-to-balloon time for ST elevated myocardial infarction patients undergoing primary Percutaneous Coronary Intervention (PCI) (where primary PCI is offered)[Before and after the intervention]